Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)-Reference-Cited by-同舟云学术

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Published:2020-02 Issue:2 Volume:31 Page:228-235
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Moehler M.^ORCID,Maderer A.,Thuss-Patience P.C.,Brenner B.,Meiler J.,Ettrich T.J.,Hofheinz R.-D.,Al-Batran S.E.,Vogel A.,Mueller L.,Lutz M.P.,Lordick F.,Alsina M.,Borchert K.,Greil R.,Eisterer W.,Schad A.,Slotta-Huspenina J.,Van Cutsem E.,Lorenzen S.

Funder

Amgen Inc.

Arbeitsgemeinschaft Internistische Onkologie

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference25 articles.

1. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial;Lancet,2002

2. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial;Vermorken;Lancet Oncol,2013

3. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial;Lordick;Lancet Oncol,2013

4. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie;Lorenzen;Ann Oncol,2009

5. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study;Douillard;J Clin Oncol,2010

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triple-pathway cGAS-STING activation collaborated with ferroptosis-induced immunogenic cell death for boosting systemic colorectal cancer immunotherapy;Nano Today;2024-12

2. Safety and Efficacy of Conversion Therapy After Systemic Chemotherapy in Advanced Esophageal Cancer with Distant Metastases: A Multicenter Retrospective Observational Study;Annals of Surgical Oncology;2024-09-12

3. Immunotherapy as a new perspective for the therapy of esophageal cancer;Innovative Surgical Sciences;2024-09-09

4. Outcomes and Prognostic Factors of Patients with Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Undergoing Immunotherapy- Versus Chemotherapy-Based Regimens: Systematic Review and Pooled Analyses;Journal of Gastrointestinal Cancer;2024-08-17

5. Treatment Strategies for Locoregional Recurrence in Esophageal Squamous-Cell Carcinoma: An Updated Review;Cancers;2024-07-14